{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T17:17:18Z","timestamp":1784308638308,"version":"3.55.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Med"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s40290-024-00545-8","type":"journal-article","created":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T03:52:19Z","timestamp":1736567539000},"page":"29-38","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Knowing is Half the Battle: The Factors Leading to Efficient Recruitment of Representative Samples in Schizophrenia Research"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5350-9623","authenticated-orcid":false,"given":"Joohyun","family":"Yoon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1175-3417","authenticated-orcid":false,"given":"Megan R.","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0665-8842","authenticated-orcid":false,"given":"Tala","family":"Berro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Brazis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1127-7016","authenticated-orcid":false,"given":"Joshua T.","family":"Kantrowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,11]]},"reference":[{"issue":"5","key":"545_CR1","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s40263-017-0428-x","volume":"31","author":"JT Kantrowitz","year":"2017","unstructured":"Kantrowitz JT. Managing negative symptoms of schizophrenia: how far have we come? CNS Drugs. 2017;31(5):373\u201388. https:\/\/doi.org\/10.1007\/s40263-017-0428-x.","journal-title":"CNS Drugs"},{"key":"545_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2024.08.019","author":"P Sehatpour","year":"2024","unstructured":"Sehatpour P, Kantrowitz JT. Finding the right dose: NMDAR modulating treatments for cognitive and plasticity deficits in schizophrenia and the role of pharmacodynamic target engagement. Biol Psychiatry. 2024. https:\/\/doi.org\/10.1016\/j.biopsych.2024.08.019.","journal-title":"Biol Psychiatry"},{"key":"545_CR3","doi-asserted-by":"publisher","DOI":"10.1177\/2045125319870033","author":"M Taylor","year":"2019","unstructured":"Taylor M, Jauhar S. Are we getting any better at staying better? The long view on relapse and recovery in first episode nonaffective psychosis and schizophrenia. Ther Adv Psychopharmacol. 2019. https:\/\/doi.org\/10.1177\/2045125319870033.","journal-title":"Ther Adv Psychopharmacol."},{"issue":"9","key":"545_CR4","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","volume":"45","author":"J Kane","year":"1988","unstructured":"Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45(9):789\u201396. https:\/\/doi.org\/10.1001\/archpsyc.1988.01800330013001.","journal-title":"Arch Gen Psychiatry"},{"issue":"12","key":"545_CR5","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1176\/ajp.151.12.1744","volume":"151","author":"JA Lieberman","year":"1994","unstructured":"Lieberman JA, Safferman AZ, Pollack S, Szymanski S, Johns C, Howard A, et al. Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry. 1994;151(12):1744\u201352. https:\/\/doi.org\/10.1176\/ajp.151.12.1744.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"545_CR6","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/s0006-3223(00)01026-x","volume":"49","author":"GD Tollefson","year":"2001","unstructured":"Tollefson GD, Birkett MA, Kiesler GM, Wood AJ, Lilly Resistant Schizophrenia study G. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol Psychiatry. 2001;49(1):52\u201363. https:\/\/doi.org\/10.1016\/s0006-3223(00)01026-x.","journal-title":"Biol Psychiatry"},{"issue":"8","key":"545_CR7","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1056\/NEJMoa2017015","volume":"384","author":"SK Brannan","year":"2021","unstructured":"Brannan SK, Sawchak S, Miller AC, Lieberman JA, Paul SM, Breier A. Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia. N Engl J Med. 2021;384(8):717\u201326. https:\/\/doi.org\/10.1056\/NEJMoa2017015.","journal-title":"N Engl J Med"},{"issue":"5","key":"545_CR8","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1093\/ijnp\/pyad011","volume":"26","author":"JT Kantrowitz","year":"2023","unstructured":"Kantrowitz JT, Correll CU, Jain R, Cutler AJ. New developments in the treatment of schizophrenia: an expert roundtable. Int J Neuropsychopharmacol. 2023;26(5):322\u201330. https:\/\/doi.org\/10.1093\/ijnp\/pyad011.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"13","key":"545_CR9","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.1038\/npp.2015.176","volume":"40","author":"RS Keefe","year":"2015","unstructured":"Keefe RS, Meltzer HA, Dgetluck N, Gawryl M, Koenig G, Moebius HJ, et al. Randomized, double-blind, placebo-controlled study of encenicline, an alpha7 nicotinic acetylcholine receptor agonist, as a treatment for cognitive impairment in schizophrenia. Neuropsychopharmacol. 2015;40(13):3053\u201360. https:\/\/doi.org\/10.1038\/npp.2015.176.","journal-title":"Neuropsychopharmacol"},{"issue":"12","key":"545_CR10","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1176\/appi.ajp.2017.17010122","volume":"174","author":"M Davidson","year":"2017","unstructured":"Davidson M, Saoud J, Staner C, Noel N, Luthringer E, Werner S, et al. Efficacy and safety of MIN-101: a 12-week randomized, double-blind, placebo-controlled trial of a new drug in development for the treatment of negative symptoms in schizophrenia. Am J Psychiatry. 2017;174(12):1195\u2013202. https:\/\/doi.org\/10.1176\/appi.ajp.2017.17010122.","journal-title":"Am J Psychiatry"},{"issue":"16","key":"545_CR11","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1056\/NEJMoa1911772","volume":"382","author":"KS Koblan","year":"2020","unstructured":"Koblan KS, Kent J, Hopkins SC, Krystal JH, Cheng H, Goldman R, et al. A non-D2-receptor-binding drug for the treatment of schizophrenia. N Engl J Med. 2020;382(16):1497\u2013506. https:\/\/doi.org\/10.1056\/NEJMoa1911772.","journal-title":"N Engl J Med"},{"issue":"3","key":"545_CR12","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S2215-0366(20)30513-7","volume":"8","author":"WW Fleischhacker","year":"2021","unstructured":"Fleischhacker WW, Podhorna J, Groschl M, Hake S, Zhao Y, Huang S, et al. Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study. Lancet Psychiatry. 2021;8(3):191\u2013201. https:\/\/doi.org\/10.1016\/S2215-0366(20)30513-7.","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"545_CR13","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1093\/schbul\/sbab095","volume":"48","author":"A Abi-Dargham","year":"2022","unstructured":"Abi-Dargham A, Javitch JA, Slifstein M, Anticevic A, Calkins ME, Cho YT, et al. Dopamine D1R receptor stimulation as a mechanistic pro-cognitive target for schizophrenia. Schizophr Bull. 2022;48(1):199\u2013210. https:\/\/doi.org\/10.1093\/schbul\/sbab095.","journal-title":"Schizophr Bull"},{"issue":"1","key":"545_CR14","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/S2215-0366(21)00386-2","volume":"9","author":"D Bugarski-Kirola","year":"2022","unstructured":"Bugarski-Kirola D, Arango C, Fava M, Nasrallah H, Liu IY, Abbs B, et al. Pimavanserin for negative symptoms of schizophrenia: results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and Europe. Lancet Psychiatry. 2022;9(1):46\u201358. https:\/\/doi.org\/10.1016\/S2215-0366(21)00386-2.","journal-title":"Lancet Psychiatry"},{"issue":"7","key":"545_CR15","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1038\/s41386-023-01560-0","volume":"48","author":"P O'Donnell","year":"2023","unstructured":"O\u2019Donnell P, Dong C, Murthy V, Asgharnejad M, Du X, Summerfelt A, et al. The D-amino acid oxidase inhibitor luvadaxistat improves mismatch negativity in patients with schizophrenia in a randomized trial. Neuropsychopharmacol. 2023;48(7):1052\u20139. https:\/\/doi.org\/10.1038\/s41386-023-01560-0.","journal-title":"Neuropsychopharmacol"},{"issue":"2","key":"545_CR16","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.biopsych.2023.01.015","volume":"94","author":"P Sehatpour","year":"2023","unstructured":"Sehatpour P, Iosifescu DV, De Baun HM, Shope C, Mayer MR, Gangwisch J, et al. Dose-dependent augmentation of neuroplasticity-based auditory learning in schizophrenia: a double-blind, placebo-controlled, randomized, target engagement clinical trial of the NMDA glutamate receptor agonist d-serine. Biol Psychiatry. 2023;94(2):164\u201373. https:\/\/doi.org\/10.1016\/j.biopsych.2023.01.015.","journal-title":"Biol Psychiatry"},{"issue":"12","key":"545_CR17","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S2215-0366(16)30344-3","volume":"3","author":"D Bugarski-Kirola","year":"2016","unstructured":"Bugarski-Kirola D, Iwata N, Sameljak S, Reid C, Blaettler T, Millar L, et al. Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme. Lancet Psychiatry. 2016;3(12):1115\u201328. https:\/\/doi.org\/10.1016\/S2215-0366(16)30344-3.","journal-title":"Lancet Psychiatry"},{"issue":"2","key":"545_CR18","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1093\/schbul\/sbv072","volume":"42","author":"D Walling","year":"2016","unstructured":"Walling D, Marder SR, Kane J, Fleischhacker WW, Keefe RS, Hosford DA, et al. Phase 2 trial of an alpha-7 nicotinic receptor agonist (TC-5619) in negative and cognitive symptoms of schizophrenia. Schizophr Bull. 2016;42(2):335\u201343. https:\/\/doi.org\/10.1093\/schbul\/sbv072.","journal-title":"Schizophr Bull"},{"issue":"3","key":"545_CR19","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1093\/schbul\/sbac013","volume":"48","author":"M Davidson","year":"2022","unstructured":"Davidson M, Saoud J, Staner C, Noel N, Werner S, Luthringer E, et al. Efficacy and safety of roluperidone for the treatment of negative symptoms of schizophrenia. Schizophr Bull. 2022;48(3):609\u201319. https:\/\/doi.org\/10.1093\/schbul\/sbac013.","journal-title":"Schizophr Bull"},{"issue":"1","key":"545_CR20","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/wps.21056","volume":"22","author":"CU Correll","year":"2023","unstructured":"Correll CU, Solmi M, Cortese S, Fava M, Hojlund M, Kraemer HC, et al. The future of psychopharmacology: a critical appraisal of ongoing phase 2\/3 trials, and of some current trends aiming to de-risk trial programmes of novel agents. World Psychiatry. 2023;22(1):48\u201374. https:\/\/doi.org\/10.1002\/wps.21056.","journal-title":"World Psychiatry"},{"key":"545_CR21","unstructured":"Otsuka America Pharmaceutical. Sumitomo pharma and Otsuka announce topline results from phase 3 DIAMOND 1 and DIAMOND 2 clinical studies evaluating ulotaront in schizophrenia. In: News Room. Princeton, NJ: Otsuka America Pharmaceutical; 2023. https:\/\/www.sumitomo-pharma.com\/news\/20230731-1.html. Accessed 27 Sept 2024."},{"key":"545_CR22","unstructured":"Neurocrine Biosciences Inc. Neurocrine Biosciences provides update on ERUDITE\u2122 phase 2 data for luvadaxistat in adults with cognitive impairment associated with schizophrenia. In: News Releases: PR Newswire; 2024. https:\/\/www.prnewswire.com\/news-releases\/neurocrine-biosciences-provides-update-on-erudite-phase-2-data-for-luvadaxistat-in-adults-with-cognitive-impairment-associated-with-schizophrenia-302246962.html. Accessed 29 Sept 2024."},{"key":"545_CR23","unstructured":"Acadia Pharmaceuticals Inc. Acadia Pharmaceuticals announces top-line results from phase 3 ADVANCE-2 trial of pimavanserin in negative symptoms of schizophrenia. In: News: Acadia Pharmaceuticals Inc.; 2024. https:\/\/acadia.com\/media\/news-releases\/acadia-pharmaceuticals-announces-top-line-results-from-phase-3-advance-2-trial-of-pimavanserin-in-negative-symptoms-of-schizophrenia\/. Accessed 29 Sept 2024."},{"issue":"11","key":"545_CR24","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1038\/s41386-019-0440-6","volume":"44","author":"S Leucht","year":"2019","unstructured":"Leucht S, Chaimani A, Mavridis D, Leucht C, Huhn M, Helfer B, et al. Disconnection of drug-response and placebo-response in acute-phase antipsychotic drug trials on schizophrenia? Meta-regression analysis. Neuropsychopharmacology. 2019;44(11):1955\u201366. https:\/\/doi.org\/10.1038\/s41386-019-0440-6.","journal-title":"Neuropsychopharmacology"},{"key":"545_CR25","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.bbi.2020.08.028","volume":"90","author":"R Jeppesen","year":"2020","unstructured":"Jeppesen R, Christensen RHB, Pedersen EMJ, Nordentoft M, Hjorthoj C, Kohler-Forsberg O, et al. Efficacy and safety of anti-inflammatory agents in treatment of psychotic disorders\u2014a comprehensive systematic review and meta-analysis. Brain Behav Immun. 2020;90:364\u201380. https:\/\/doi.org\/10.1016\/j.bbi.2020.08.028.","journal-title":"Brain Behav Immun"},{"issue":"6","key":"545_CR26","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1097\/00004714-200012000-00001","volume":"20","author":"DS Robinson","year":"2000","unstructured":"Robinson DS, Rickels K. Concerns about clinical drug trials. J Clin Psychopharmacol. 2000;20(6):593\u20136. https:\/\/doi.org\/10.1097\/00004714-200012000-00001.","journal-title":"J Clin Psychopharmacol"},{"issue":"12","key":"545_CR27","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1097\/j.pain.0000000000000333","volume":"156","author":"AH Tuttle","year":"2015","unstructured":"Tuttle AH, Tohyama S, Ramsay T, Kimmelman J, Schweinhardt P, Bennett GJ, et al. Increasing placebo responses over time in US clinical trials of neuropathic pain. Pain. 2015;156(12):2616\u201326. https:\/\/doi.org\/10.1097\/j.pain.0000000000000333.","journal-title":"Pain"},{"key":"545_CR28","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.schres.2018.05.009","volume":"201","author":"S Leucht","year":"2018","unstructured":"Leucht S, Chaimani A, Leucht C, Huhn M, Mavridis D, Helfer B, et al. 60 years of placebo-controlled antipsychotic drug trials in acute schizophrenia: meta-regression of predictors of placebo response. Schizophr Res. 2018;201:315\u201323. https:\/\/doi.org\/10.1016\/j.schres.2018.05.009.","journal-title":"Schizophr Res"},{"key":"545_CR29","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.schres.2022.01.013","volume":"242","author":"DC Javitt","year":"2022","unstructured":"Javitt DC, Kantrowitz JT. The glutamate\/N-methyl-d-aspartate receptor (NMDAR) model of schizophrenia at 35: on the path from syndrome to disease. Schizophr Res. 2022;242:56\u201361. https:\/\/doi.org\/10.1016\/j.schres.2022.01.013.","journal-title":"Schizophr Res"},{"key":"545_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-019-0557-8","author":"C Donde","year":"2019","unstructured":"Donde C, Martinez A, Kantrowitz JT, Silipo G, Dias EC, Patel GH, et al. Bimodal distribution of tone-matching deficits indicates discrete pathophysiological entities within the syndrome of schizophrenia. Transl Psychiatry. 2019. https:\/\/doi.org\/10.1038\/s41398-019-0557-8.","journal-title":"Transl Psychiatry"},{"issue":"1","key":"545_CR31","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1093\/schbul\/sbab090","volume":"48","author":"BA Clementz","year":"2022","unstructured":"Clementz BA, Parker DA, Trotti RL, McDowell JE, Keedy SK, Keshavan MS, et al. Psychosis biotypes: replication and validation from the B-SNIP consortium. Schizophr Bull. 2022;48(1):56\u201368. https:\/\/doi.org\/10.1093\/schbul\/sbab090.","journal-title":"Schizophr Bull"},{"issue":"2","key":"545_CR32","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.psychres.2003.11.002","volume":"125","author":"CM Loughland","year":"2004","unstructured":"Loughland CM, Carr VJ, Lewin TJ, Barnard RE, Chapman JL, Walton JM. Potential sampling and recruitment source impacts in schizophrenia research. Psychiatry Res. 2004;125(2):117\u201327. https:\/\/doi.org\/10.1016\/j.psychres.2003.11.002.","journal-title":"Psychiatry Res"},{"key":"545_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2018.00654","author":"J Lally","year":"2018","unstructured":"Lally J, Watkins R, Nash S, Shetty H, Gardner-Sood P, Smith S, et al. The representativeness of participants with severe mental illness in a psychosocial clinical trial. Front Psychiatry. 2018. https:\/\/doi.org\/10.3389\/fpsyt.2018.00654.","journal-title":"Front Psychiatry."},{"key":"545_CR34","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.schres.2017.07.032","volume":"191","author":"M Lee","year":"2018","unstructured":"Lee M, Sehatpour P, Dias EC, Silipo GS, Kantrowitz JT, Martinez AM, et al. A tale of two sites: differential impairment of frequency and duration mismatch negativity across a primarily inpatient versus a primarily outpatient site in schizophrenia. Schizophr Res. 2018;191:10\u20137. https:\/\/doi.org\/10.1016\/j.schres.2017.07.032.","journal-title":"Schizophr Res"},{"key":"545_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev.publhealth.27.021405.102113","volume":"27","author":"AK Yancey","year":"2006","unstructured":"Yancey AK, Ortega AN, Kumanyika SK. Effective recruitment and retention of minority research participants. Annu Rev Public Health. 2006;27:1\u201328. https:\/\/doi.org\/10.1146\/annurev.publhealth.27.021405.102113.","journal-title":"Annu Rev Public Health"},{"key":"545_CR36","doi-asserted-by":"publisher","DOI":"10.2196\/22810","author":"I Darmawan","year":"2020","unstructured":"Darmawan I, Bakker C, Brockman TA, Patten CA, Eder M. The role of social media in enhancing clinical trial recruitment: scoping review. J Med Internet Res. 2020. https:\/\/doi.org\/10.2196\/22810.","journal-title":"J Med Internet Res"},{"key":"545_CR37","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.cct.2018.08.002","volume":"72","author":"CP Lee","year":"2018","unstructured":"Lee CP, Holmes T, Neri E, Kushida CA. Deception in clinical trials and its impact on recruitment and adherence of study participants. Contemp Clin Trials. 2018;72:146\u201357. https:\/\/doi.org\/10.1016\/j.cct.2018.08.002.","journal-title":"Contemp Clin Trials"},{"key":"545_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsams.2015.12.196","author":"S Alley","year":"2015","unstructured":"Alley S, Jennings C, Plotnikoff R, Vandelanotte C. An evaluation of web- and print-based methods to attract people to a physical activity intervention. J Sci Med Sport. 2015. https:\/\/doi.org\/10.1016\/j.jsams.2015.12.196.","journal-title":"J Sci Med Sport"},{"issue":"1","key":"545_CR39","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/jamia\/ocy138","volume":"26","author":"E Pfaff","year":"2019","unstructured":"Pfaff E, Lee A, Bradford R, Pae J, Potter C, Blue P, et al. Recruiting for a pragmatic trial using the electronic health record and patient portal: successes and lessons learned. J Am Med Inform Assoc. 2019;26(1):44\u20139. https:\/\/doi.org\/10.1093\/jamia\/ocy138.","journal-title":"J Am Med Inform Assoc"},{"issue":"6","key":"545_CR40","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1177\/1740774520933362","volume":"17","author":"SJ Salvy","year":"2020","unstructured":"Salvy SJ, Carandang K, Vigen CL, Concha-Chavez A, Sequeira PA, Blanchard J, et al. Effectiveness of social media (Facebook), targeted mailing, and in-person solicitation for the recruitment of young adult in a diabetes self-management clinical trial. Clin Trials. 2020;17(6):664\u201374. https:\/\/doi.org\/10.1177\/1740774520933362.","journal-title":"Clin Trials"},{"key":"545_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.comppsych.2020.152197","author":"C Sanchez","year":"2020","unstructured":"Sanchez C, Grzenda A, Varias A, Widge AS, Carpenter LL, McDonald WM, et al. Social media recruitment for mental health research: a systematic review. Compr Psychiatry. 2020. https:\/\/doi.org\/10.1016\/j.comppsych.2020.152197.","journal-title":"Compr Psychiatry"},{"key":"545_CR42","doi-asserted-by":"publisher","DOI":"10.2196\/23021","author":"R Pozzar","year":"2020","unstructured":"Pozzar R, Hammer MJ, Underhill-Blazey M, Wright AA, Tulsky JA, Hong F, et al. Threats of bots and other bad actors to data quality following research participant recruitment through social media: cross-sectional questionnaire. J Med Internet Res. 2020. https:\/\/doi.org\/10.2196\/23021.","journal-title":"J Med Internet Res"},{"issue":"11","key":"545_CR43","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1093\/ijnp\/pyac058","volume":"25","author":"E Deckler","year":"2022","unstructured":"Deckler E, Ferland M, Brazis S, Mayer MR, Carlson M, Kantrowitz JT. Challenges and strategies for the recruitment of patients with schizophrenia in a research setting. Int J Neuropsychopharmacol. 2022;25(11):924\u201332. https:\/\/doi.org\/10.1093\/ijnp\/pyac058.","journal-title":"Int J Neuropsychopharmacol"},{"key":"545_CR44","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.19m12786","author":"MF Brunette","year":"2020","unstructured":"Brunette MF, Correll CU, O\u2019Malley SS, McDonnell D, DiPetrillo L, Jiang Y, et al. Olanzapine plus samidorphan (ALKS 3831) in schizophrenia and comorbid alcohol use disorder: a phase 2, randomized clinical trial. J Clin Psychiatry. 2020. https:\/\/doi.org\/10.4088\/JCP.19m12786.","journal-title":"J Clin Psychiatry"},{"issue":"12","key":"545_CR45","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/S2215-0366(23)00288-2","volume":"10","author":"JM Kane","year":"2023","unstructured":"Kane JM, Harary E, Eshet R, Tohami O, Weiser M, Leucht S, et al. Efficacy and safety of TV-46000, a long-acting, subcutaneous, injectable formulation of risperidone, for schizophrenia: a randomised clinical trial in the USA and Bulgaria. Lancet Psychiatry. 2023;10(12):934\u201343. https:\/\/doi.org\/10.1016\/S2215-0366(23)00288-2.","journal-title":"Lancet Psychiatry"},{"issue":"3","key":"545_CR46","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/s41386-021-01170-8","volume":"47","author":"P Sehatpour","year":"2022","unstructured":"Sehatpour P, Javitt DC, De Baun HM, Carlson M, Beloborodova A, Margolin DH, et al. Mismatch negativity as an index of target engagement for excitation\/inhibition-based treatment development: a double-blind, placebo-controlled, randomized, single-dose cross-over study of the serotonin type-3 receptor antagonist CVN058. Neuropsychopharmacology. 2022;47(3):711\u20138. https:\/\/doi.org\/10.1038\/s41386-021-01170-8.","journal-title":"Neuropsychopharmacology"},{"key":"545_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2018.02.280","author":"L Jarskog","year":"2018","unstructured":"Jarskog L, Stroup T. Metformin and 5-HT2C agonist lorcaserin for weight loss in schizophrenia. Biol Psychiatry. 2018. https:\/\/doi.org\/10.1016\/j.biopsych.2018.02.280.","journal-title":"Biol Psychiatry"},{"issue":"5","key":"545_CR48","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1111\/eip.13083","volume":"15","author":"RSE Keefe","year":"2021","unstructured":"Keefe RSE, Woods SW, Cannon TD, Ruhrmann S, Mathalon DH, McGuire P, et al. A randomized phase II trial evaluating efficacy, safety, and tolerability of oral BI 409306 in attenuated psychosis syndrome: design and rationale. Early Interv Psychiatry. 2021;15(5):1315\u201325. https:\/\/doi.org\/10.1111\/eip.13083.","journal-title":"Early Interv Psychiatry"},{"issue":"4","key":"545_CR49","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.brs.2019.03.003","volume":"12","author":"JT Kantrowitz","year":"2019","unstructured":"Kantrowitz JT, Sehatpour P, Avissar M, Horga G, Gwak A, Hoptman MJ, et al. Significant improvement in treatment resistant auditory verbal hallucinations after 5 days of double-blind, randomized, sham controlled, fronto-temporal, transcranial direct current stimulation (tDCS): a replication\/extension study. Brain Stimul. 2019;12(4):981\u201391. https:\/\/doi.org\/10.1016\/j.brs.2019.03.003.","journal-title":"Brain Stimul"},{"issue":"1","key":"545_CR50","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1093\/schbul\/sbaa107","volume":"47","author":"EC Dias","year":"2021","unstructured":"Dias EC, Sheridan H, Martinez A, Sehatpour P, Silipo G, Rohrig S, et al. Neurophysiological, oculomotor, and computational modeling of impaired reading ability in schizophrenia. Schizophr Bull. 2021;47(1):97\u2013107. https:\/\/doi.org\/10.1093\/schbul\/sbaa107.","journal-title":"Schizophr Bull"},{"key":"545_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2024.103570","author":"A Martinez","year":"2024","unstructured":"Martinez A, Gaspar PA, Bermudez DH, Belen Aburto-Ponce M, Beggel O, Javitt DC. Disrupted third visual pathway function in schizophrenia: evidence from real and implied motion processing. Neuroimage Clin. 2024. https:\/\/doi.org\/10.1016\/j.nicl.2024.103570.","journal-title":"Neuroimage Clin."},{"issue":"1","key":"545_CR52","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41398-023-02656-3","volume":"13","author":"P Sehatpour","year":"2023","unstructured":"Sehatpour P, Kreither J, Lopez-Calderon J, Shastry AM, De Baun HM, Martinez A, et al. Network-level mechanisms underlying effects of transcranial direct current stimulation (tDCS) on visuomotor learning in schizophrenia. Transl Psychiatry. 2023;13(1):360. https:\/\/doi.org\/10.1038\/s41398-023-02656-3.","journal-title":"Transl Psychiatry"},{"key":"545_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.629144","author":"P Sehatpour","year":"2020","unstructured":"Sehatpour P, Avissar M, Kantrowitz JT, Corcoran CM, De Baun HM, Patel GH, et al. Deficits in pre-attentive processing of spatial location and negative symptoms in subjects at clinical high risk for schizophrenia. Front Psychiatry. 2020. https:\/\/doi.org\/10.3389\/fpsyt.2020.629144.","journal-title":"Front Psychiatry."},{"key":"545_CR54","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.schres.2023.02.018","volume":"254","author":"M Cecchi","year":"2023","unstructured":"Cecchi M, Adachi M, Basile A, Buhl DL, Chadchankar H, Christensen S, et al. Validation of a suite of ERP and QEEG biomarkers in a pre-competitive, industry-led study in subjects with schizophrenia and healthy volunteers. Schizophr Res. 2023;254:178\u201389. https:\/\/doi.org\/10.1016\/j.schres.2023.02.018.","journal-title":"Schizophr Res"},{"issue":"4","key":"545_CR55","doi-asserted-by":"publisher","first-page":"523","DOI":"10.3122\/jabfm.2010.04.090096","volume":"23","author":"CB Felsen","year":"2010","unstructured":"Felsen CB, Shaw EK, Ferrante JM, Lacroix LJ, Crabtree BF. Strategies for in-person recruitment: lessons learned from a New Jersey primary care research network (NJPCRN) study. J Am Board Fam Med. 2010;23(4):523\u201333. https:\/\/doi.org\/10.3122\/jabfm.2010.04.090096.","journal-title":"J Am Board Fam Med"},{"key":"545_CR56","doi-asserted-by":"publisher","DOI":"10.2196\/24055","author":"S Allan","year":"2021","unstructured":"Allan S, McLeod H, Bradstreet S, Bell I, Whitehill H, Wilson-Kay A, et al. Perspectives of trial staff on the barriers to recruitment in a digital intervention for psychosis and how to work around them: qualitative study within a trial. JMIR Hum Factors. 2021. https:\/\/doi.org\/10.2196\/24055.","journal-title":"JMIR Hum Factors"},{"key":"545_CR57","doi-asserted-by":"publisher","DOI":"10.2196\/resprot.4268","author":"SR Partridge","year":"2015","unstructured":"Partridge SR, Balestracci K, Wong AT, Hebden L, McGeechan K, Denney-Wilson E, et al. Effective strategies to recruit young adults into the TXT2BFiT mHealth randomized controlled trial for weight gain prevention. JMIR Res Protoc. 2015. https:\/\/doi.org\/10.2196\/resprot.4268.","journal-title":"JMIR Res Protoc."},{"key":"545_CR58","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.drugalcdep.2018.07.011","volume":"191","author":"GE Hunt","year":"2018","unstructured":"Hunt GE, Large MM, Cleary M, Lai HMX, Saunders JB. Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990\u20132017: systematic review and meta-analysis. Drug Alcohol Depend. 2018;191:234\u201358. https:\/\/doi.org\/10.1016\/j.drugalcdep.2018.07.011.","journal-title":"Drug Alcohol Depend"}],"container-title":["Pharmaceutical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-024-00545-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40290-024-00545-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-024-00545-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T17:30:09Z","timestamp":1741109409000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40290-024-00545-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["545"],"URL":"https:\/\/doi.org\/10.1007\/s40290-024-00545-8","relation":{},"ISSN":["1178-2595","1179-1993"],"issn-type":[{"value":"1178-2595","type":"print"},{"value":"1179-1993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"12 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Internal funding (NYSPI) to J.T.K.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"There are no known conflicts that are directly relevant to this work. Dr. Kantrowitz has received consulting payments within the last 36 months from Alphasights, CME Outfitters, Evoke, S.R. One, techspert.io, Health Monitor, Third Bridge, MEDACorp, Marketplus, FCB Health, Trinity, Globaldata, GKA, Clearview, Clarivate, Health Advances, ECRI Institute, ExpertConnect, Slingshot, Antheum, Guidepoint, First Thought, Wedbush, VMLY&R, Bluestar BioAdvisors, Jefferies, Reckner, Medscape, SmartAnalyst, Putnam, Ascel, VoxNeuro, and Otsuka. He has served on the Medincell, Merck, Leal, and Karuna Advisory Boards in the past 36 months. He has conducted clinical research supported by the National\u00a0Institute of\u00a0Mental\u00a0Health, Sunovion, Roche, Click, Neurocrine, Taisho, and Boehringer Ingelheim within the last 36 months. He owns a small number of shares of common stock from GSK. The other authors declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Ethics approval was obtained under our IRB approved screening protocol, which includes a waiver of consent\/documentation of consent for participants who are not screened in person. Our screening protocol is in accordance with the ethical standards of our institution and with the 1964 Helsinki Declaration and its later amendments.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable (not a clinical trial).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable (no identifiable data).","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The datasets generated during and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"IBM\u00ae SPSS\u00ae Statistics version 29 was used for all analyses.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Joohyun Yoon: conceptualization, methodology, formal analysis, investigation, writing\u2014original draft, writing\u2014review and editing, and visualization. Megan R. Mayer: writing\u2014review and editing. Tala Berro: writing\u2014review and editing. Stephanie Brazis: investigation. Joshua Kantrowitz: conceptualization, methodology, writing\u2014original draft, writing\u2014review and editing, and supervision. All authors have read and approved the final submitted manuscript and agree to be accountable for the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}